Posted by Michael Wonder on 06 Dec 2023
BridgeBio Pharma announces submission of new drug application to US FDA for acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy
5 December 2023 - NDA submission is based on positive results from ATTRibute-CM Phase 3 study.
BridgeBio Pharma today announced that it has submitted an NDA for acoramidis to the US FDA for the treatment of transthyretin amyloid cardiomyopathy.
